Novel DZ-artemisinin for treatment of pancreatic cancer

Ended Project Grant Awarded Last action

Award ID
W81XWH2210551
Recipient
Awarding agency
Obligated
$1,903,318

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Funding
  • $951,659.00 Federal
  • $951,659.00 Non-federal
Place of performance
West Hollywood, CA 90048, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

Cedars-Sinai Medical Center was awarded a $1.9 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to support research on novel DZ-artemisinin for treatment of pancreatic cancer. The three-year award will fund preclinical research from August 2022 to August 2025 to investigate medical solutions for pancreatic cancer on the battlefield and for the American public through innovative biomedical research. Specifically, the grant will support Cedars-Sinai's efforts to transform health care by developing new drug therapies for pancreatic cancer using DZ-artemisinin, an antimalarial compound, which may lead to more effective treatment options.

Quick answers

Who received award W81XWH2210551?

W81XWH2210551 was awarded to Cedars-Sinai Medical Center by Medical Command (Department of the Army) on August 15, 2022.

How much is award W81XWH2210551 worth?

$1,903,318 has been obligated on W81XWH2210551: $951,659 in federal funding and $951,659 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login